Month: June 2022

Ashvattha Therapeutics Announces Presentation of Preclinical Data at the 2022 Neurofibromatosis (NF) Conference Demonstrating the Potential of Hydroxyl Dendrimer Therapeutics to Reduce Toxicity in Targeted Treatment of Plexiform Neurofibroma

by

Scientific collaborators at Indiana University School of Medicine presented preclinical data showing Ashvattha’s hydroxyl dendrimers (HDs) were selectively taken up only within tumor-associated microglia/macrophages in a mouse model of NF1 These findings suggest that therapeutic conjugation of HDs to target cells of plexiform neurofibroma (PNF) tumor microenvironment may be efficacious and minimize toxicity in the … Read more

Ashvattha Therapeutics Announces Poster Presentation of Preclinical Data on Hydroxyl Dendrimer-Based Therapeutics at the 2022 Neurofibromatosis (NF) Conference

by

– Scientific collaborators at Indiana University School of Medicine will present preclinical data demonstrating Ashvattha’s hydroxyl dendrimer-based therapeutics reduce toxicity in targeted delivery to plexiform neurofibroma – REDWOOD CITY, Calif., June 7, 2022 – Ashvattha Therapeutics (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced a poster presentation of preclinical data demonstrating … Read more